American Portfolios Advisors’s Moleculin Biotech MBRX Stock Holding History

American Portfolios Advisors’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$354	Hold	1	–	–	﹤0.01%	3424
2022 Q2	$484	Hold	1	–	–	﹤0.01%	3395
2022 Q1	$595	Hold	1	–	–	﹤0.01%	3445
2021 Q4	$621	Hold	1	–	–	﹤0.01%	3388
2021 Q3	$1K	Hold	1	–	–	﹤0.01%	3303
2021 Q2	$1.23K	Hold	1	–	–	﹤0.01%	3227
2021 Q1	$1.36K	Hold	1	–	–	﹤0.01%	3078
2020 Q4	$1.59K	Hold	1	–	–	﹤0.01%	2750
2020 Q3	$1.63K	Hold	1	–	–	﹤0.01%	2668
2020 Q2	$1.94K	Hold	1	–	–	﹤0.01%	2560
2020 Q1	$1.22K	Hold	1	–	–	﹤0.01%	2520
2019 Q4	$1.83K	Hold	1	–	–	﹤0.01%	2593
2019 Q3	$2.22K	Hold	1	–	–	﹤0.01%	2490
2019 Q2	$2.5K	Hold	1	–	–	﹤0.01%	2412
2019 Q1	$1.62K	Hold	1	–	–	﹤0.01%	2416
2018 Q4	$2.08K	Hold	1	–	–	﹤0.01%	2131
2018 Q3	$2.4K	Hold	1	–	–	﹤0.01%	2199
2018 Q2	$2.69K	Buy	+1	New	+$4.09K	﹤0.01%	2147

Other funds holding MBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

American Portfolios Advisors's MBRX Position: Q3 2022 in Review

American Portfolios Advisors held its Moleculin Biotech (MBRX) position steady in Q3 2022 at 1 share worth $354. The position accounts for ﹤0.01% of the portfolio, ranked #3424.

American Portfolios Advisors first reported a position in MBRX in Q2 2018 and has held it in 18 quarters since. The position peaked at $2.69K in Q2 2018. 24 funds tracked by Wall St. Rank hold MBRX as of Q3 2022.

American Portfolios Advisors held 1 share of Moleculin Biotech worth $354 as of Q3 2022.
American Portfolios Advisors left its Moleculin Biotech share count unchanged in Q3 2022.
Moleculin Biotech made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #3424 holding.
American Portfolios Advisors first reported a position in Moleculin Biotech in Q2 2018 and has held it in 18 quarters since.
American Portfolios Advisors's Moleculin Biotech position peaked at $2.69K in Q2 2018.
24 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.